ProQR Therapeutics (NASDAQ:PRQR – Get Rating) was downgraded by equities research analysts at StockNews.com from a “hold” rating to a “sell” rating in a note issued to investors on Wednesday.
Several other brokerages have also recently commented on PRQR. Raymond James raised their target price on ProQR Therapeutics from $2.00 to $5.00 and gave the stock an “outperform” rating in a research report on Friday, December 23rd. Cantor Fitzgerald upgraded ProQR Therapeutics from a “neutral” rating to an “overweight” rating and set a $5.00 price objective for the company in a research note on Thursday, December 22nd. One analyst has rated the stock with a sell rating, one has given a hold rating and three have issued a buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Hold” and a consensus price target of $3.90.
ProQR Therapeutics Stock Up 7.8 %
Shares of PRQR stock opened at $3.16 on Wednesday. The stock has a market cap of $225.28 million, a P/E ratio of -2.93 and a beta of 0.12. ProQR Therapeutics has a one year low of $0.53 and a one year high of $3.78. The stock has a fifty day moving average price of $3.04 and a 200 day moving average price of $1.87. The company has a debt-to-equity ratio of 0.07, a current ratio of 3.86 and a quick ratio of 3.86.
Institutional Inflows and Outflows
About ProQR Therapeutics
ProQR Therapeutics NV is a clinical stage biopharmaceutical company. It is engaged in the discovery and development of RNA therapies for the treatment of severe genetic rare diseases with a focus on inherited retinal diseases, such as Leber congenital amaurosis 10, Usher syndrome type 2, and autosomal dominant retinitis pigmentosa.
- Get a free copy of the StockNews.com research report on ProQR Therapeutics (PRQR)
- Monoclonal Antibodies? Avid Bioservices surges 32% on Blowout Q3
- GitLab Crashes On Guidance; Analysts Defend
- Healthcare Stocks With at Least 30 Years of Dividend Increases
- Coinbase Pops As SVB Crumbles To Dust
- Airlines Update Guidance, Shares Head For Different Destinations
Receive News & Ratings for ProQR Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProQR Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.